77242113PSO3006 Enrolling

Plaque Psoriasis Study (25 Months)


Treatment: Oral Age: 12+ Years


Who Can Participate?

Those aged 12 years or older with moderate to severe plaque psoriasis may participate.

 

Inclusion Criteria

      • have a diagnosis of moderate to severe plaque psoriasis with duration of at least 26 weeks
      • for participants aged 12 years or older but less than 18 years, must have a body weight of 40 kg more

 

Participant Information

      • Participate and receive study treatment at no cost
      • Regular visits with study doctors who specialise in treating plaque psoriasis (20 visits)
      • Will receive either an investigational oral treatment (study drug), a comparator*, or a placebo
      • Have plaque psoriasis on 10% or more of your body surface area (BSA)*
      • Reimbursement for study-related expenses may be provided

*The comparator is a treatment already used for the treatment of plaque psoriasis.

*10% BSA is the equivalent of about 10 palm print’s worth of surface area.

 

How Long Will The Study Last?

      • 108 weeks (approximately 25 months)

Note: Participants will need to stop all other treatments for plaque psoriasis during clinical trial participation. Some over-the-counter preparations may be deemed acceptable by the doctor performing the study.


Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: May 15, 2025

Official Title

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov ID

NCT06934226

Sponsor

Janssen Research & Development, LLC

Study Description

  • Brief Summary:

    The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

  • Condition or Disease:

    Plaque Psoriasis

  • Intervention/Treatment:

    Drug: JNJ-77242113,Drug: Matching Placebo to Ustekinumab Drug: JNJ-77242113,Drug: Matching Placebo to JNJ-77242113,Drug: Matching Placebo to Ustekinumab Drug: JNJ-77242113,Drug: Matching Placebo to JNJ-77242113,Drug: Ustekinumab
  • Phase:

    PHASE 3

  • Ages Eligible for Study:

    12 Years and older (CHILD,ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Psoriasis

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content